Trials / Completed
CompletedNCT01993888
The EVARREST® Fibrin Sealant Patch Liver Study
A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST® Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Ethicon, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and hemostatic effectiveness of EVARREST® Fibrin Sealant Patch (EVARREST) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EVARREST® Fibrin Sealant Patch | |
| OTHER | Standard of Care (SoC) |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2014-07-01
- Completion
- 2014-09-01
- First posted
- 2013-11-25
- Last updated
- 2016-07-11
- Results posted
- 2016-07-11
Locations
17 sites across 4 countries: United States, Australia, New Zealand, United Kingdom
Source: ClinicalTrials.gov record NCT01993888. Inclusion in this directory is not an endorsement.